United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
438.18
+18.97 (4.53%)
At close: Oct 1, 2025, 4:00 PM EDT
440.00
+1.82 (0.42%)
After-hours: Oct 1, 2025, 7:42 PM EDT
United Therapeutics Revenue
United Therapeutics had revenue of $798.60M in the quarter ending June 30, 2025, with 11.71% growth. This brings the company's revenue in the last twelve months to $3.08B, up 17.62% year-over-year. In the year 2024, United Therapeutics had annual revenue of $2.88B with 23.63% growth.
Revenue (ttm)
$3.08B
Revenue Growth
+17.62%
P/S Ratio
6.39
Revenue / Employee
$2,358,467
Employees
1,305
Market Cap
19.82B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.88B | 549.90M | 23.63% |
Dec 31, 2023 | 2.33B | 391.20M | 20.20% |
Dec 31, 2022 | 1.94B | 250.80M | 14.88% |
Dec 31, 2021 | 1.69B | 202.20M | 13.63% |
Dec 31, 2020 | 1.48B | 34.50M | 2.38% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
UTHR News
- 3 days ago - United Therapeutics Corporation - Special Call - Seeking Alpha
- 8 days ago - United Therapeutics Corporation (UTHR) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 12 days ago - United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis - Business Wire
- 15 days ago - United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum - Business Wire
- 19 days ago - United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress - Business Wire
- 23 days ago - United Therapeutics Corporation (UTHR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 27 days ago - United Therapeutics: Nebulized Tyvaso Label Expansion Possible For IPF After Study Win - Seeking Alpha
- 4 weeks ago - United Therapeutics: Is UTHR Stock Still A Buy At $400? - Forbes